Efficacy of IMOD in the treatment of oral lichen planus—Efficacy of IMOD in oral lichen planus

Farzaneh Agha-Hosseini, Iraj Mirzaii-Dizgah, Mohammad Abdollahi, Neda Akbari-Gillani

.

DOI: 10.4236/ojst.2011.12003                

Abstract

Objectives: Oral lichen planus (OLP) is a chronic, immunologically mediated, mucocutaneous disorder. A wide range of topical and systemic therapies have been used in the treatment of OLP. The efficacy of IMOD (an Iranian new immunomodulator drug, con- taining selenium, carotene, and flavonoids) in the management of oral lichen planus was evaluated. Study design: In a before-after clinical trial study, thirty patients (21 women and 9 men; age range 35 - 66 years with 112 lesions) with lichen planus were enrolled. The study covered a three-month period of therapy by IMOD (400 mg/day) and a three-month follow-up period after drug cessation. Outcome mea- sures include soreness relief based on the “nu-meric scale”, and clinical improvement of lesion size and score. Saliva levels of TNF-α was analysed at the baseline and after treatment by ELISA. Statistical analysis of Wilcoxon and paired student’s t-test were used. Results: Approximately 85% of patients showed partial to complete improvement and re-mained sym- ptom free after drug cessation. There was no signifi-cant difference in mean saliva TNF-α level before and after the treatment. Conclusion: These results suggest that IMOD seems to be an effective alternative treat- ment for OLP and TNF-α may not be a good indica- tor for monitoring therapeutic response of OLP.

Keywords

Oral Lichen Planus; IMOD; TNF-α

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ismail, S.B., Kumar, S.K. and Zain, R.B. (2007) Oral lichen planus and lichenoid reactions: Etiopathogenesis, diagnosis, management and malignant transformation. Journal of Oral Sciences, 49, 89-106. doi:10.2334/josnusd.49.89
[2]	Agha-Hosseini, F., Mirzaii-Dizgah, I., Mikaili, S. and Abdollahi, M. (2009) Increased salivary lipid pero- xidation in human subjects with oral lichen planus. International Journal of Dental Hygiene, 7, 246-250. doi:10.1111/j.1601-5037.2009.00365.x
[3]	Greenberg S. (2008) Burket’s oral medicine. 11th Edition, BC Decker Inc, Hamilton, 89-94.
[4]	Gorouhi, F., Solhpour, A., Beitollahi, J.M., Afshar, S., Davari, P., Hashemi, P., Nassiri Kashani, M. and Firooz, A. (2007) Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus. Journal of the American Academy of Dermatology, 57, 806-813. doi:10.1016/j.jaad.2007.06.022
[5]	Khairandish, P., Mohraz, M., Farzamfar, B., Abdollahi, M., Shahhosseiny, M.H. and Madani, H. (2009) Preclinical and phase 1 clinical safety of Setarud (IMOD?), a novel immunomodulator. 17, 148-156.
[6]	Zhang, Y., Lin, M., Zhang, S., Wang, Z., Jiang, L., Shen, J., Bai, J., Gao, F., Zhou M. and Chen, Q. (2008) NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: A study in an ethnic. Chinese population Cytokine, 41, 144-149. doi:10.1016/j.cyto.2007.11.004
[7]	Pezelj-Ribaric S., Prso, I.B., Abram, M., Glazar, I., Brumini, G. and Simunovic-Soskic, M. (2004) Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators of Inflammation, 13, 131-133. doi:10.1080/09629350410001688530
[8]	Banno, T., Gazel, A. and Blumenberg, M. (2004) Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional pro- filing. The Journal of Biological Chemistry, 279, 32633- 32642. doi:10.1074/jbc.M400642200
[9]	van der Meij, E. H. and van der Waal, I. (2003) Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. Journal of Oral Pathology & Medicine, 32, 507-512. doi:10.1034/j.1600-0714.2003.00125.x
[10]	Thongprasom, K., Luangjarmekorn, L., Sererat T. and Taweesap, W. (1992) Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. Journal of Oral Pathology & Medicine, 21, 456-458. doi:10.1111/j.1600-0714.1992.tb00974.x
[11]	Agha-Hosseini, F., Borhan-Mojabi, K., Monsef-Esfahani, H.R., Mirzaii-Dizgah, I., Etemad-Moghadam S. and Karagah, A. (2010) Efficacy of Purslane in the treatment of oral lichen planus. Phytotherapy Research, 24, 240-244.
[12]	Mohraz, M., Khairandish, P., Kazerooni, P.A., Da- varpanah, M.A., Shahhosseiny, M.H., Mahdavian, B., Vaziry, S., Shahriary, S., Kamali, K., Khorram Khorshid, H.R., Heshmat, R., Farhadi M. and Gharibdoust, F. (2009) A clinical trial on the efficacy of IMOD in AIDS patients. 17, 277-284.
[13]	Aghahosseini, F., Arbabi-Kalati, F., Fashtami, L.A., Djavid, G.E., Fateh M. and Beitollahi, J.M., (2006) Methylene blue-mediated photodynamic therapy: A possible alternative treatment for oral lichen planus. Lasers in Surgery and Medicine, 38, 33-38. doi:10.1002/lsm.20278
[14]	Rhodus, N.L., Cheng, B., Bowles, W., Myers, S., Miller L. and Ondrey, F. (2006) Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Diseases, 12, 112-116. doi:10.1111/j.1601-0825.2005.01165.x
[15]	Lodi, G., Tarozzi, M., Sardella, A., Demarosi, F., Cane- gallo, L., Di Benedetto, D. and Carrassi, A. (2007) Miconazole as adjuvant therapy for oral lichen planus: a double-blind randomized controlled trial. British Journal of Dermatology, 156, 1336-1341. doi:10.1111/j.1365-2133.2007.07883.x
[16]	Payvandi, F., Wu, L., Naziruddin, S.D., Haley, M., Parton, A., Schafer, P.H., Chen, R.S., Muller, G.W., Hughes, C.C. and Stirling, D.I. (2005) Immunomo- dulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT. Journal of Interferon & Cytokine Research, 25, 604-616. doi:10.1089/jir.2005.25.604